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Abstract 
 
Background: 5-aminolevulinic acid (5-ALA) has demonstrated to be a safe and 
useful tool for real-time intraoperative identification of tumor tissue, leading to 
extensive resections which are associated with increased survival for patients 
with high-grade gliomas. Although tumors in eloquent areas can constrain 
resection due to higher risk of neurological deficits, this should not contra-
indicate 5-ALA judicious use. 
Objective: To evaluate the impact of resection in progression-free survival 
(PFS) and overall survival (OS), the postoperative complications and learning 
after the first 100 cases of 5-ALA fluorescence-guided resection in a tertiary 
referral hospital. 
Methods: A retrospective study of the first 100 cases of newly diagnosed brain 
lesions submitted to fluorescence-guided surgery with 5-ALA, from 2012 to 
2016. Only glioblastoma patients were considered for the statistical analysis. 
We analyzed the influence of 5-ALA in the extent of resection considering tumor 
in eloquent and non-eloquent location, post-operative neurological deficits, PFS 
and OS. 
Results:  Gross total resection (GTR) was achieved in 73% of patients with 
tumors in non-eloquent areas and in 43,4% in eloquent areas. Partial resection 
was superior in tumors located in eloquent areas (34,0%vs13,5%). There were 
no significant differences in postoperative neurological deficits amongst distinct 
extents of resection (p=0,228) or tumor location (p=0,670). Mean PFS for all 
group was 9,73±1,19 months and mean OS for all group was 16,27±1,39 
months. GTR>90% and the non-eloquent area of the tumor were correlated with 
a significant increase in PFS but the extent of resection was the only 
independent factor for PFS in multivariate analysis. Regarding OS, no 
independent prognosis factor was established in the multivariate analysis. 
Conclusion: 5-ALA is an important tool in glioblastoma surgery, contributing for 
GTR and, consequently, to increase PFS. Although its use has not raised 
neurological deficits, it must be carefully used in eloquent located tumors. 
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Introduction 
The extent of resection has been recognized as an established 
prognostic factor in the treatment of glioblastoma (GBM) [13,1], being the only 
one potentially modifiable. Complete resection of enhancing tumor is linked to 
an improvement in survival [2,17,16,13,21], acting synergistically with optimized 
medical treatment [18].  
Multiple techniques were developed in order to achieve a better 
identification of the tumor from adjacent normal brain, being fluorescence-
guided resection with 5-aminolevulinic acid (5-ALA) one of the most innovative. 
5-ALA is a metabolic precursor in the heme pathway and can be used as 
an oral prodrug that leads to the synthesis and accumulation of fluorescent 
porphyrins, mainly protoporphyrin IX, in high-grade glioma cells [20,19,15].  
Several studies have showed that 5-ALA intraoperative fluorescence has 
a very high sensitivity, specificity and positive predictive value (PPV) for 
malignant tumor tissue [22,15,7,26,23,11,8,10]. Additionally, there are two 
patterns of fluorescence: “strong”, associated with solid and proliferating tumor 
and “weak” corresponding to infiltrating tumor with both tumor and normal cells. 
These patterns correlate with sensitivity, specificity and PPV, and has been 
found that these values can reach 100% in areas with “strong” fluorescence 
[23,7,11,12,10], confirming the remarkable diagnostic precision of 5-ALA.  
Introduced by Stummer et al.[22], it has since demonstrated to be a 
secure and accurate tool for real-time intraoperative identification of tumor cells, 
leading to extensive tumor removal and an increase in survival for patients with 
high-grade gliomas[20,19,5]. It remains inconsistent in the literature if the 
increased survival expresses progression-free survival or overall survival. 
However, it cannot be ignored that more radical resections carry more 
risks of neurological damages [24], particularly in tumors near eloquent areas. 
The aim of using 5-ALA in eloquent areas is not to achieve gross total resection 
(GTR) but increase the accuracy for tumor cells. While some authors only use 
immunofluorescence in cases of expected GTR, our understanding is that 5-
ALA also helps in defining tumor cells even in cases only suitable for partial 
resections (PR). 
The goals of the present study are to evaluate the impact of the extent of 
tumor resection in progression-free survival and overall survival, the possible 
post-surgical complications and the lessons learned after the first 100 cases 
using fluorescence-guided resection with 5-ALA. 
 
Materials and Methods  
Patient population 
The data used in this study was obtained from clinical records of the first 
100 cases submitted to fluorescence-guided surgery with 5-ALA, from May 
2012 until February 2016 in a European Union University Hospital.  All medical 
record reviews were conducted with approval from the Local Ethical Committee. 
For this type of study formal consent is not required. 
The criteria for the use of 5-ALA were newly diagnosed brain lesions with 
MRI suggestive of high grade malignant glioma in patients eligible for open 
surgery, according to their clinical status.  
Tumors were categorized as located in eloquent and non-eloquent areas. 
The primary motor cortex (precentral gyrus), primary somatosensory 
cortex (postcentral gyrus), occipital visual cortex, insula, corpus callosum and 
the operculum area in the frontal, parietal and temporal left lobes were 
considered eloquent areas. 
From a total of 100 patients submitted to surgery with 5-ALA, 90 were 
diagnosed with GBM after histopathological confirmation. In the remaining 10 
patients, 3 were diagnosed with anaplastic astrocytoma and 7 with different 
histological types. Due to the diversity of diagnoses, patients who were not 
diagnosed with GBM were excluded in the further analysis. Table 1 shows the 
patient and tumor baseline characteristics. 
 
Technical principals 
5-ALA (Gliolan, Medac, Wedel, Germany) oral solution was administered 
to patients at 20mg/kg bodyweight, 2-4h before general anesthesia. 
Dexamethasone was also provided to all patients at least two days before 
surgery up to the postoperative MRI, less than 72h after surgery. It has been 
reported that dexamethasone use improves fluorescence. 
The tumor was resected using a surgical microscope (Zeiss OPMI 
Pentero 900® or Leica OHS®) that is able to switch from white conventional light 
(no fluorescence visible) to violet-blue light (BL400) whenever desired by the 
neurosurgeon, allowing fluorescent tumor tissue identification. The goal of the 
surgery was to remove safely all the fluorescent tissue visible, considering 
possible neurological deterioration when near to eloquent areas. Other 
intraoperative diagnostic tools, such as neuronavigation and awake monitoring 
were used. 
The extent of resection was assessed by comparison of preoperative 
MRI with postoperative MRI less than 72h after surgery and then classified as 
GTR, subtotal resection (STR) or PR. GTR was defined as absence of residual 
contrast in post-op MRI; the resection was considered subtotal when was 
superior to 90% of the volume but not complete; PR included less than 90% of 
the tumor volume removed.  
 
 Treatment and follow up 
After diagnostic confirmation of GBM, patients were referred to a neuro-
oncology multidisciplinary team (MDT) meeting to evaluate their clinical 
conditions to pursue further treatment.  
From the patients diagnosed with GBM, 76 started the Stupp protocol, 
radiotherapy with concomitant and adjuvant temozolomide[25], one patient with 
recurrent brain lesion started second-line chemotherapy after surgery and six 
patients were referred to palliative care. Seven patients were not submitted to 
any treatment after surgery due to their condition (n=6) or treatment refusal 
(n=1) and were submitted to best supportive care. 
Progression was defined as an increase in residual tumor volume, the 
occurrence of a new tumor lesion or deterioration in the clinical status, 
according to RANO criteria. After progression, the neuro-oncology MDT would 
decide whether to start second-line chemotherapy, re-operate or refer to 
palliative chemotherapy according to the clinical and functional condition of 
each patient. 
 
Statistical analysis 
The statistical analysis was performed using IBM SPSS® (Statistical 
Package for Social Sciences) version 24. Statistical significance was set at 
p<0,05. It was conducted a descriptive analysis of all variables.  
To test the possible effect of multiple factors like age, sex, preoperative 
KPS and area of the tumor (eloquent/non-eloquent) in the extent of resection, 
separately Chi-square tests were performed. It was also accessed the influence 
of the resection on post-operative neurological deficits with a Chi-square test.  
Progression-free survival and overall survival were defined as the time 
between surgery and progression or time of death, respectively. To identify 
factors influencing survival, Kaplan-Meier survival curves were constructed 
individually for sex, age, preoperative KPS, tumor eloquence and extent of 
resection. For survival analysis, the extent of resection was grouped in gross 
total/subtotal (tumor removal superior to 90%) and partial resection due to the 
quantitative difference of tumor not removed. 
It was also analyzed if the extent of resection suffered a variation through 
with time, comparing the extent of resection of the first 45 patients with GBM 
submitted to 5-ALA guided-resection with the last 45 patients. 
 
Results 
Resection 
Patients were divided in two groups: tumors in non-eloquent areas 
(n=37) and tumors in eloquent areas (n=53). It was observed a significant 
difference in the extent of resection between the groups (p=0,019) (FIG1). GTR 
was accomplished in 73% of patients with non-eloquent tumors, 13,5% had 
STR and 13,5% PR, which means that it was obtained a resection >90% in 
86,5% of patients.  Concerning tumors in eloquent areas, resections >90% were 
achieved in 66% being GTR 43,4% of the patients, 22,6% had STR of the tumor 
and 34,0% had PR. Even though in both groups GTR was achieved more often 
than subtotal or partial, these results demonstrate a bigger proportion of gross 
total removal in tumors in non-eloquent areas and a higher percentage of PR in 
eloquent areas, what was expected since the aim of resection in eloquent areas 
were the maximal safe resection and not GTR. 
Factors which could have influenced the extent of resection such as age, 
sex, preoperative KPS and time within series (Table 2) were also considered. 
The analysis demonstrated that sex, age and preoperative KPS could not prove 
to be significant prognosis factors even though it appears that a GTR is 
accomplished more frequently in younger patients or with KPS score superior to 
70. The extent of resection did not suffer a variation when comparing the first 45 
patients submitted to 5-ALA guided resection with the latter 45 patients. 
 
Safety 
 Post-operative complications were divided in de novo epilepsy (n=2), 
hemorrhagic/ ischemic events (n=3), infection (n=2) and new/aggravation of 
focal deficit (n=20). The majority of patients (70%) have not developed any 
complication. KPS score 1 month after surgery remained identical to pre-op 
KPS score (median=90).  
 From all the post-operative complications detected, it was considered 
that only new/aggravation of focal deficit could result from the use of 5-ALA 
since its main goal is to improve the extent of resection, which can ultimately 
lead to neurological deterioration. It was also considered if focal deficits could 
vary with the area of the tumor (eloquent/non-eloquent) as eloquent areas 
would be more prone to subsequent deficits.  
  After analysis, no difference in post-op focal deficit was found amongst 
tumors in eloquent areas comparing with non-eloquent areas (p=0,670). 
Moreover, the neurological deficits have not diverged when compared between 
gross total, subtotal or partial resection (p=0,228).  
 
Survival 
Mean overall survival for all group was 16,27 ± 1,39 months and mean 
progression-free survival for all group was 9,73 ± 1,19 months. 
For the analysis of survival, potential prognosis factors were evaluated 
such as sex, patient age, preoperative KPS score, localization of tumor and the 
extent of resection. 
Patient age inferior to 65 years old (<65 = 18,01±1,57 months vs ³65 
=13,22±2,31 months; p=0,043) and a preoperative KPS score superior to 70 
(KPS>70=17,36±1,54 months vs KPS£70=10,13±2,00 months; p=0,028) were 
significantly associated with longer overall survival. Extent of resection 
(GTR>90%=17,52±1,68 months vs PR=13,130±2,62 months; p=0,107) and 
tumor area (eloquent=13,71±1,32 months vs non-eloquent=19,32±2,41 months; 
p=0,077) failed to demonstrate a significant association, even though it appears 
to exist a tendency for improvement of overall survival when the resection is 
>90% or the tumor is located in a non-eloquent area (FIG. 2). No independent 
prognosis factor for overall survival was established in the multivariate analysis. 
Furthermore, a complete resection (GTR>90%=11,33±1,54 months vs 
PR=5,30±0,93 months; p=0,001), the non-eloquent area of the tumor 
(eloquent=7,15±0,81 months vs non-eloquent=13,58±2,59 months; p=0,007) 
and once again, the preoperative KPS score superior to 70 
(KPS>70=10,48±1,37 months vs KPS£70=5,49±1,10 months; p=0,028)  
showed a significant increase in progression-free survival. The difference in 
patient age was not statistically significant in progression-free survival 
(<65=9,78±1,17 months vs  ³65=9,22±2,25 months; p=0,308) (FIG 3). 
Multivariate analysis was performed, showing that resection superior to 90% is 
the only independent factor for progression-free survival (p=0,030) 
There were no differences in overall survival (male=17,07±2,03 months 
vs female=14,83±1,57months; p=0,590) or progression-free survival 
(male=9,66±1,50 months vs female=9,19±1,51months; p=0,820) related with 
gender.  
     
Discussion 
Glioblastoma is the most common malignant primary brain tumor and it is 
associated with a very poor prognosis. Tumor removal has a major role in 
treatment, being proven that the extent of resection is an important prognosis 
factor for patient survival [21,17,16,13,2,1]. This led to the development of 5-
ALA with the goal of achieving more radical resections thus improving survival. 
[22,21,20] 
Multiple studies revealed GTR rates superior to 60% using 5-ALA, 
representing a major improvement from “white-light” surgery [20,19,8,7,3]. 
Although 5-ALA is used mostly in patients were the goal is GTR, we used it in 
all patients with glioblastoma regardless of the expected extent of resection. 
Because of this, we divided our results in two different groups, the one that is 
expected a GTR and the group which STR was the aim because of an eloquent 
area is present. Tumors in eloquent areas have a particular importance due to 
increased risk of neurological damage and can substantially limit the resection. 
One must not forget the importance of the quality of life in patients with such a 
short life expectancy and improving resection does not fulfill its goal if 
accompanied with new or aggravation of neurological deficits and can even 
decrease overall survival.[14] These leads to differences in the extent of 
resection when comparing tumors in eloquent and non-eloquent areas. 
In the present study, resection >90% of tumor volume was observed in 
86,5% and GTR in 73% of patients with tumors located in non-eloquent areas, 
in contrast with only 66% with resection >90% and 43,4% with complete 
absence of contrast of tumors located near an eloquent area. On the other 
hand, the proportion of PR and STR was superior in tumors adjacent to 
eloquent areas. These results reflect a careful approach to the use of 5-ALA 
specially in eloquent areas, not removing all the fluorescent tissue that is 
observed intraoperatively to prevent further neurological damages. Other 
intraoperative diagnostic tools were used, but in order to achieve better results 
in resection it has been suggested the use of intraoperative monitoring in 
combination with 5-ALA in all tumors located in eloquent areas. [9,6] 
It was detected that the extent of resection did not suffer a modification 
when comparing the first 45 patients submitted to 5-ALA guided resection with 
the latter 45 patients. This lack of variation through time can be rationalized by 
the fact that few surgeons started performing this type of surgery progressively 
and their diverse learning curves. 
 Regarding safety, some authors described a temporarily neurological 
impairment in patients with more radical resections[24]. We have not 
experienced differences in postoperative focal deficit amongst tumors in 
eloquent areas comparing with non-eloquent areas or when compared between 
GTR, STR or PR, although this can be consequence of the careful approach 
and higher proportion of PR and STR in eloquent tumors. 
Our mean overall survival for all group was 16,27 ± 1,39 months and 
mean progression-free survival for all group was 9,73 ± 1,19 months which is 
concordant with the results in the literature [11] even with lower resection rates.  
Exploring overall survival, we observed that younger ages and a good 
preoperative status were significantly associated with longer overall survival in 
univariate analysis but not in multivariate analysis. Additionally, it appeared to 
exist a non-significant tendency for improvement of overall survival when the 
tumor is located in a non-eloquent area or the resection is >90%, what would be 
consistent with previous results referring a survival benefit in resections superior 
to 70% [17,2]. In spite of that, OS could be a controversial end-point owing to 
the difficulty to control treatments and interventions after progression. In fact, 
Bloch et al.[4] stated that the extent of resection at recurrence can be an 
essential predictor of overall survival. The differences in post-recurrence 
treatments or re-operations were outside the sphere of this work but could 
explain the lack of statistical significance in respect of resection and OS. 
A significant improvement in progression-free survival was noted with 
GTR>90%, the non-eloquent area of the tumor and a favorable preoperative 
status. In multivariate analysis, resection superior to 90% was the only 
independent factor. PFS was also the clinical benefit described by Stummer et 
al.[20]  
Concerning limitations, the retrospective design of the study and the 
small sample size are important factors and can explain the lack of statistical 
significance in some variables. Further prospective studies with larger samples 
are needed to help recognize statistical significance in all the analysis a 
tendency was acknowledged and to improve the evidence level for the use of 5-
ALA guided resection.  
 
Conclusions: 
5-ALA is an important tool in glioblastoma surgery, contributing for GTR 
and, consequently, to duplicate PFS from 5,30 to 11,33 months. Although its 
use has not raised neurological deficits, it must be carefully used in eloquent 
tumors. Our data were according to the literature, showing better results when 
5-ALA were used in tumors in non-eloquent areas where the aim is to achieve 
gross total resection. 
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Table 1. Patient and tumor characteristics n=100 
Gender Male 52 
 Female 48 
Age Range 26-80 
 Mean 58,73 
±11,91 
 Median 61 
Pre-operative KPS Range 20-100 
 Median 90 
 >70 84 
 £70 16 
Tumor location Eloquent 58 
 Non-eloquent 42 
Histology GBM 90 
 Anaplastic astrocytoma 3 
 Anaplastic 
oligodendroglioma 
1 
 Anaplastic ependymoma  1 
 Grade II astrocytoma 1 
 Grade II oligodendroglioma 1 
 Grade III meningioma  1 
 Necrosis 1 
 Vasculitis 1 
Treatment after surgery: 
GBM 
Stupp protocol  76 
 Bevacizumab+irinotecan 1 
 Palliative care  6 
 Best supportive care 7 
 
Table 2. Cross tabulation  
  Resection   
  Partial 
(n=23) 
Subtotal 
(n=17) 
Gross 
total 
(n=50) 
Total 
(n=90) 
p 
Sex Male 13 5 29 47 0,112 
 Female 10 12 21 43 
Age <65 11 10 35 56 0,183 
 ³65 12 7 15 34 
KPS pre-
op 
£70 7 3 5 15 0,093 
 >70 16 14 45 75 
Patients 1-45 13 9 23 45 0,680 
 45-90 10 8 26 45  
 
FIG 1. Different extents of resection stratified by eloquent/non-eloquent area of 
tumor (p=0,019) 
  
  
A. B. 
  
C. D. 
E.  
 
FIG. 2. Graphs showing Kaplan-Meier overall survival curves. A. Overall 
survival – 16,27 ± 1,39 months B. Survival stratified by age – <65 = 18,01±1,57 
months; ³65 =13,22±2,31 months. C. Survival stratified by preoperative KPS 
score - KPS>70=17,36±1,54 months; KPS£70=10,13±2,00 months. D. Survival 
stratified by tumor area (eloquent/non-eloquent) – eloquent =13,71±1,32 months 
(median=12,00±1,55); non-eloquent =19,32±2,41 months. E. Survival stratified by 
extent of resection – GTR>90%=17,52±1,68 months; PR =13,130±2,62 months. 
 
  
A. B. 
  
C. D. 
E.  
FIG. 3. Graphs showing Kaplan-Meier progression-free survival curves. A. 
Progression-free survival – 9,73 ± 1,19 months. B. Survival stratified by age – 
<65=9,78±1,17 months; ³65=9,22±2,25 months. C. Survival stratified by 
preoperative KPS score - KPS>70=10,48±1,37 months; KPS£70=5,49±1,10 
months. D. Survival stratified by tumor area (eloquent/non-eloquent) – 
eloquent=7,15±0,81 months; non-eloquent=13,58±2,59 months. E. Survival 
stratified by extent of resection – GTR>90%=11,33±1,54 months; PR=5,30±0,93 
months.  
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